Know Cancer

forgot password

Pilot Randomized Study of Aerobic and Resistance Exercise for Women Undergoing Treatment for Breast Cancer With Taxanes.

19 Years
Not Enrolling
Peripheral Nervous System Disorders, Breast Neoplasms, Chemotherapy

Thank you

Trial Information

Pilot Randomized Study of Aerobic and Resistance Exercise for Women Undergoing Treatment for Breast Cancer With Taxanes.

This pilot study will test the effects of a tailored home-based walking (aerobic) and
strength training (resistance) exercise program for individuals receiving taxane-based
chemotherapy for breast cancer on neuropathy, breast cancer-related symptoms, cold thermal
sensation, vibratory sensation, gait & balance, upper and lower extremity muscle strength,
and quality of life.

The objective of this pilot study is to determine the effect size, feasibility and
acceptability of a 12-week combination exercise program consisting of aerobic exercise
(walking) and strength training for preventing or ameliorating the clinical manifestations
and symptoms of CIPN in individuals with Stage I-IIIa non-metastatic breast cancer.

Inclusion Criteria:

- age 19 or older with newly diagnosed Stage I-IIIa invasive breast cancer who are to
be treated with a taxane-based chemotherapy regimen (with paclitaxel or docetaxel)
and thus are at risk for the development of CIPN.

Exclusion Criteria:

- any disease (e.g. diabetes, HIV) that results in peripheral neuropathy;

- any disease or disorder that results in muscle weakness (such as chronic fatigue
syndrome, multiple sclerosis, spinal cord tumors or injuries, stroke, preexisting
cardiopulmonary disease);

- any disease or disorder that would preclude strength training exercises (such as bone
metastasis, osteoporosis);

- individuals with diagnosed lymphedema or advanced disease (> Stage IIIa, or
metastatic disease) at high risk for bone metastases and pathologic fracture will be

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Outcome Measure:

effect size for reduction of neuropathic symptoms

Outcome Time Frame:

Baseline, 4, 8 12, 24 weeks

Safety Issue:


Principal Investigator

Constance Visovsky, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Nebraska


United States: Institutional Review Board

Study ID:




Start Date:

April 2009

Completion Date:

June 2011

Related Keywords:

  • Peripheral Nervous System Disorders
  • Breast Neoplasms
  • Chemotherapy
  • breast cancer
  • chemotherapy-induced peripheral neuropathy
  • exercise
  • Breast Neoplasms
  • Neoplasms
  • Nervous System Diseases
  • Peripheral Nervous System Diseases



University of Nebraska Medical CenterOmaha, Nebraska  68198-3330